Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease.
TLDR
A brief review article is intended to cover the recent advances in drug development and emerging therapeutic agents for Alzheimer's disease acting at different targets as discussed by the authors, which is concluded that novel therapeutic strategies are required to discover and develop therapeutic agents to fight against the century old AD.Abstract:
Alzheimer’s disease (AD) is a neurodegenerative old age disease that is complex, multifactorial, unalterable, and progressive in nature. The currently approved therapy includes cholinesterase inhibitors, NMDA-receptor antagonists and their combination therapy provides only temporary symptomatic relief. Sincere efforts have been made by the researchers globally to identify new targets, discover, and develop novel therapeutic agents for the treatment of AD. This brief review article is intended to cover the recent advances in drug development and emerging therapeutic agents for AD acting at different targets. The article is compiled using various scientific online databases and by referring to clinicaltrials.gov and ALZFORUM (alzforum.org) websites. The upcoming therapies act on one or more targets including amyloids (secretases, Aβ42 production, amyloid deposition, and immunotherapy), tau proteins (tau phosphorylation/aggregation and immunotherapy) and neuroinflammation in addition to other miscellaneous targets. Despite the tremendous improvement in our understanding of the underlying pathophysiology of AD, only aducanumab was approved by FDA for the treatment of AD in 18 years i.e., since 2003. Hence, it is concluded that novel therapeutic strategies are required to discover and develop therapeutic agents to fight against the century old AD.read more
Citations
More filters
Journal ArticleDOI
The China Alzheimer Report 2022
Ru-Jing Ren,Jinlei Qi,Shaohui Lin,Xinya Liu,Peng Yin,Zhihui Wang,Ran Tang,Jin Tao Wang,Qiang Huang,Jianping Li,Xin-Yi Xie,Yong-Bo Hu,Shi-Shuang Cui,Yuan-chao Zhu,Pengfei Wang,Yikang Zhu,Yiran Wang,Yanyan Huang,Yisong Hu,Ying Wang,Chunbo Li,Gang Wang +21 more
TL;DR: The public health impact of ADRD, including prevalence, mortality, costs, usage of care, and the overall effect on caregivers and society is examined, as well as an information platform for international exchange and cooperation is suggested.
Journal ArticleDOI
Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.
TL;DR: Based on the recent research focus on the novel cholinesterase inhibitors with multiple bio-functions, a review aims at summarizing and discussing the most recent studies excavating the potential carbamate-based MTDLs with choline inhibition efficacy, to accelerate the pace of pleiotropic choline-based inhibitors for coping Alzheimer's disease as discussed by the authors .
Journal ArticleDOI
Synthesis, characterization, and biological evaluation of some novel Schiff bases as potential metabolic enzyme inhibitors
TL;DR: A series of novel Schiff base derivatives containing a pyrazolone ring (2a–e) were designed, successfully synthesized for the first time, and characterized by elemental analysis and some spectroscopic methods, finding that some of the Schiffbase derivatives may be used as potential drug candidates in later studies.
Journal ArticleDOI
Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease
Qi Wang,Xiaomin Huang,Yixun Su,Guowei Yin,Shouyu Wang,Bin Yu,Hui Li,Junhua Qi,Hui Chen,Wencong Zeng,Kai Zhang,Alexei Verkhratsky,Jianqin Niu,Chenju Yi +13 more
TL;DR: Targeting LRP6 in the Wnt/β-catenin pathway in the brain endothelium can alleviate BBB malfunction induced by Aβ, which may be a potential treatment strategy for AD.
Journal ArticleDOI
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
TL;DR: In this paper , the authors present a review of Alzheimer's disease treatment strategies, summarizing clinical features and pharmacological properties, along with molecular docking analyses of the existing medications, and present phase I, II, and III studies that act on several fronts, such as cognitive improvement, symptom reduction, and enhancing the basic biology of AD.
References
More filters
Journal ArticleDOI
Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.
Ann M. Saunders,Warren J. Strittmatter,Donald E. Schmechel,P. St. George-Hyslop,Margaret A. Pericak-Vance,S. H. Joo,B.L. Rosi,James F. Gusella,D. R. Crapper-MacLachlan,Mark J. Alberts,Christine M. Hulette,Barbara J. Crain,Dmitry Goldgaber,A. D. Roses +13 more
TL;DR: Data support the involvement of ApoE ϵ4 in the pathogenesis of late-onset familial and sporadic AD and suggest it may operate as a susceptibility gene (risk factor) for the clinical expression of AD.
Journal ArticleDOI
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
TL;DR: Glycogen synthase kinase-3 (GSK3) must be particularly adaptable for incorporating new substrates into its repertoire, and the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways are discussed.
Journal ArticleDOI
The Genetics of Alzheimer Disease: Back to the Future
TL;DR: It seems likely that much of the heritability of AD continues to remain unexplained by the currently known disease genes, and much of this "missing heritability" may be accounted for by rare sequence variants, which, owing to recent advances in high-throughput sequencing technologies, can be assessed in unprecedented detail.
Journal ArticleDOI
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Robert Howard,Rupert McShane,James Lindesay,Craig W. Ritchie,Ashley Baldwin,Robert Barber,Alistair Burns,Tom Dening,David Findlay,Clive Holmes,Alan Hughes,Robin Jacoby,Robert G. Jones,Roy W. Jones,Ian G. McKeith,Ajay Macharouthu,John T. O'Brien,Peter Passmore,Bart Sheehan,Edmund Juszczak,Cornelius Katona,Robert Kerrin Hills,Martin Knapp,Clive Ballard,Richard G. Brown,Sube Banerjee,Caroline Onions,Mary Griffin,Jessica Adams,Richard Gray,Tony Johnson,Peter Bentham,Patrick P. J. Phillips +32 more
TL;DR: In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months.
Journal ArticleDOI
Clearing the brain's amyloid cobwebs.
TL;DR: Understanding how proteolysis regulates Abeta levels in the cerebral cortex has implications for both the pathogenesis and the treatment of this protean disorder.
Related Papers (5)
Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules.
Tarana Umar,Nasimul Hoda +1 more